Share on LinkedInShare on LinkedIn

VIDEO · 22 JULY 2013

Risk Adjustment & Assessment In The Payor Universe (Video Content)

Goodwin Procter LLP
Explore more from Goodwin Procter LLP

Closing the Healthcare Growth Cap Conference on April 11th, 2013, Stuart Rosenthal, Partner in the Business Law Department at Goodwin Procter moderates a panel that addresses three critical themes.

United StatesFood, Drugs, Healthcare, Life Sciences
Goodwin Procter LLP
Goodwin Procter LLP

self

Closing the Healthcare Growth Cap Conference on April 11th, 2013, Stuart Rosenthal, Partner in the Business Law Department at Goodwin Procter moderates a panel that addresses three critical themes. Lending their seasoned perspectives, panelists Shan Padda of Health Integrated, Jack McCallum of CenseoHealth, Keith R. Dunleavy of Inovalon and Sundar Subramanian of Booz & Company, discuss how payors are working to better understand their underlying members, what they are doing to assess risk and the impact of health reform. Continuing to answer key questions such as, what effect will exchanges and "qualified health plans" have on the need to assess and adjust risk, what do the next 3-5 years look like for payors and how more consumer directed healthcare and increased member engagement changes the equation.

View the complete Healthcare Growth Cap Conference agenda at http://growthcapcon.com/agenda/

Related Articles

Legal Intelligence Newsletters

Read more about

Related Comparative Guides

See more popular content from

Article

FDA Seeks Public Feedback On Regulatory Approach For Generative AI-Enabled Medical Devices

The U.S. Food and Drug Administration has released a discussion paper outlining its initial framework for regulating generative AI-enabled medical devices, proposing a two-axis risk assessment approach and a novel competency-based premarket evaluation system. With public comments due by October 19, 2026, this represents a critical opportunity for device manufacturers and stakeholders to shape the regulatory landscape for this transformative technology.
United StatesFood, Drugs, Healthcare, Life Sciences
Katten
Katten
Article

FDA Balances Peptide Policy With Enforcement Against Unlawful Peptide Sellers

Over the past year, industry has had a front row seat as the Food and Drug Administration (“FDA” or the “Agency”) decides just how much leeway it wants to afford the manufacture, marketing, and sale of peptide products, and just where it wants to draw the line. Despite the recent decision of FDA’s Pharmacy Compounding Advisory Committee (“PCAC”) to recommend a number of peptides for inclusion on the 503A bulks list process — a move that represents a potentially more permissive stance toward peptide regulation, at least in terms of what can and cannot be compounded under 503A...
United StatesFood, Drugs, Healthcare, Life Sciences
Sheppard
Sheppard
Article

California OHCA Issues Final Regulations Implementing Expanded Health Care Transaction Review Requirements For Private Equity, Hedge Funds, And MSOs

On Friday, California Office of Health Care Affordability (“OHCA”) published proposed final regulations that implement a 2026 law that significantly expanded OHCA’s review authority over health care transactions involving private equity (“PE”) groups, hedge funds, and management services organizations (“MSOs”). Stakeholders involved in California health care transactions should re-assess whether their ongoing or contemplated transactions are implicated by these regulations, because newly covered transactions will need to comply with the 90-day advance notice requirement established in the original OHCA regulations.
United StatesFood, Drugs, Healthcare, Life Sciences
Simpson Thacher & Bartlett LLP
Simpson Thacher & Bartlett LLP
Article

FDA Holds Landmark Public Hearing On The Future Therapeutic Use Of Psychedelic Drugs

The FDA, in collaboration with federal partners, held a landmark public hearing on September 14, 2026, to gather input on the future therapeutic use of psychedelic drugs, drawing over 18,000 registered attendees. This hearing represents one of the earliest implementations of Executive Order 14401, which directs federal agencies to expedite research, review, and approval of psychedelic drugs for serious mental health conditions.
United StatesFood, Drugs, Healthcare, Life Sciences
Foley Hoag LLP
Foley Hoag LLP
Article

Federal Regulators And State Boards Crack Down On RUO Peptides

The FDA has escalated enforcement against online peptide sellers through warning letters and criminal prosecution, while state medical boards impose stricter standards on prescribers. Recent actions reveal how research-use-only disclaimers fail when evidence shows intended human use, and one case resulted in a 70-month prison sentence combined with $5 million forfeiture.
United StatesFood, Drugs, Healthcare, Life Sciences
McDermott Will & Schulte
McDermott Will & Schulte
Article

Pharmaceutical Policy In Motion Continued: The Trump Administration’s Second Wave Of Drug Pricing Deals

The Trump administration's most-favored-nation pricing initiative has expanded to include nine additional mid-sized pharmaceutical manufacturers, bringing the total coverage to 89% of the brand drug market. These new agreements focus on Medicaid pricing discounts aligned with international rates, while manufacturers commit billions to U.S. manufacturing and research in exchange for exemptions from future pricing mandates and potential tariffs.
United StatesFood, Drugs, Healthcare, Life Sciences
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.